Navigation Links
NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
Date:7/24/2008

SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The results revealed no unexpected safety findings and efficacy was maintained for the one-year duration of the study, as measured by the patients' global assessment scale. In addition, the results showed that the patients' mean blood pressure was stable for 52 weeks following the completion of the 301 study, suggesting that naproxcinod does not increase blood pressure over time. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

The 301 safety extension study was conducted in 92 clinical centers in the United States and enrolled the first 500 eligible patients with osteoarthritis of the knee who successfully completed the 301 phase 3 study for naproxcinod (see press releases of June 13, 2008 and November 12, 2007). NicOx expects to announce the top-line efficacy results from the ongoing 302 and 303 pivotal phase 3 studies for naproxcinod in the second half of 2008, ahead of a projected New Drug Application (NDA) in mid-2009.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "The data from this open label trial form an important part of our long term safety database for naproxcinod. We are happy with the good overall safety we have observed in this study and look forward to gaining further 52 week data from the 302 study, which includes an active control arm."

The 302 study is being conducted in patients with osteoarthritis of the knee and efficacy is being measured at 13 weeks by the same three co-primary endpoints as in the 301 and 303 studies. In addition, th
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
6. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
7. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
8. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
9. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
10. NicOx Naproxcinod ABPM Data Presented at American Heart Association
11. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today announced ... financial results on Tuesday, Jan. 27, 2015, after the close of ... conference call with the investment community at 2 p.m. PT. Participating ... , chairman and chief executive officer, and other members of Amgen,s ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... South Dakota pharmaceutical company, pharmaCline ™ , has launched ... statement.  On November 23, 2011, pharmaCline became a part ... spot on the CBS jumbo screen located in Times ... through January 1, 2012. (Logo:  http://photos.prnewswire.com/prnh/20111202/MN16158LOGO ...
... Dec. 1, 2011 Demands from senior management ... commercial functions searching for best-in-class organizational structures. Comparing ... in place at peer companies through benchmarking data ... To support pharmaceutical vice presidents, directors, ...
Cached Medicine Technology:pharmaCline Launches "pharmaCline Can Help" Campaign 2Organizational Design and Structure Benchmarks for Pharmaceutical Commercial Functions Accessed Quickly Through Best Practices, LLC's New Database Search Function 2
(Date:1/22/2015)... The City of West Hollywood hosted a news ... the 42nd anniversary of the Supreme Court decision Roe v. Wade, ... years since the Roe vs. Wade decision and the fight to ... ever,” said City of West Hollywood Councilmember Abbe Land. “We need ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... 16 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or the ... provider of,pharmacy benefits management services, announces that effective June ... Executive Officer (CEO),will retire from the position of CEO, ... Officer, will be appointed President and CEO.,Both will continue ...
... Through emotional and,energetic performances, Garth Brooks, Jon McLaughlin, ... Hearing Foundation, a world leader in,promoting hearing health ... the World May Hear" Awards Gala, held Saturday, ... With money raised at the Gala, the Starkey,Hearing ...
... Celestial,Group, Inc. (Nasdaq: HAIN ), a leading natural ... that Irwin D. Simon, President and,Chief Executive Officer, will ... 18th at 9:30 AM., (Logo: http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ), ... Celestial Group started to,Change the Way the World Eats ...
... important to medicine in the 19th,& 20th century, Behavioral Medicine ... an important component of Behavioral Medicine, Dr. John ... Basmajian, Member of the Order of Canada, ... Sport,Psychologists that trained Canada,s top Olympic athletes will be teaching ...
... "Nearly 500,000,Americans die of sudden cardiac death per ... untimely passing of Mr. Tim Russert," according to ... Associates of Los,Angeles. He adds that, "Sudden cardiac ... or asystole. These are brought,on by severe coronary ...
... between chilhood overweight and higher readings , , MONDAY, ... blood pressure in childhood are also prone to hypertension ... studies conducted over four decades in different countries. ... tracks from childhood to adulthood and that elevated blood ...
Cached Medicine News:Health News:SXC Health Solutions announces Mark Thierer to be named President & CEO 2Health News:Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser 2Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 2Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 3Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 4Health News:Biofeedback Workshops & Distance Learning Offer Credits and Training Options 2Health News:Tim Russert's Sudden Cardiac Death May Have Been Preventable 2Health News:High Blood Pressure in Kids Tracks Into Adulthood 2
DiaMed-ID Micro Typing System...
ScanGel® Incubator...
... Three different sized High-Throughput Submarine Systems ... of samples from microtitre plates. Analyze ... fragments, synthetic oligos or PCR products ... pipetting for accuracy and speed with ...
... The Mini-PROTEAN 3 Dodeca cell runs up ... in just 35 minutes. Handcast gels can ... the new Model 485 gradient former and ... variation and improving reproducibility. Alternatively, Ready Gel ...
Medicine Products: